GAINESVILLE, FL--(Marketwired - August 23, 2013) - Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has received a Notice-of-Allowance for an additional new U.S. patent that will protect its novel, non-leaching NIMBUS® antimicrobial technology.
The U.S. Patent and Trademark Office has allowed all 41 claims in Quick-Med Technologies' U.S. Patent Application No. 12/830,062 titled, "POLYELECTROLYTE COMPLEX FOR IMPARTING ANTIMICROBIAL PROPERTIES TO A SUBSTRATE." This new patent will provide protection for an improved method of preparing the company's NIMBUS antimicrobial products. The method utilizes a Poly-Electrolyte Complex, or PEC in which a negatively-charged (anionic) polymer is used to stabilize the active antimicrobial agent -- a positively-charged (cationic) polymer. This complex allows the NIMBUS polymer to be bonded to a wider variety of substrates, opening the door for new applications and products.
"The PEC method is an important improvement in the way we manufacture our NIMBUS materials," said Dr. William Toreki, one of the inventors of the method, and Quick-Med's Vice-President of Research & Development. "The PEC makes the antimicrobial component more adherent on a molecular level, and that makes it easier to attach it to the surfaces of bandages and wound dressings." The PEC method is currently in-use in commercial products such as the BIOGUARD
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.
While NIMBUS antimicrobials remain at full strength, the active agent in most other antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the risk of irritation or interference with healing in products such as wound dressings and textile applications in which the treated material is next to or used on the skin. The bonding of an antimicrobial to a substrate is a paradigm shift from the current state-of-the-art which fosters release of the active agent. The value of a non-leaching antimicrobial is that it does not allow depletion of the active agent which can lead to damage to human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate the development of bacterial resistance.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS
© 2013 Quick-Med Technologies, Inc. All rights reserved. NIMBUS
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.